Provepharm Life Solutions identifies new therapeutic uses for mature molecules, with a focus on antidotes and surgical dyes. Its platform redefines purity requirements for active ingredients to maximize therapeutic potential and explore untouched indications. The company developed a patented synthesis method for methylene blue, enabling marketing authorizations in more than 30 countries. Provepharm is using recent funding to hire staff in France and the United States and to expand its laboratories in Marseille. The firm is headquartered in Marseille with an operation in Philadelphia, employs over 90 people, and reported turnover of €48.5m in 2020. It was founded in 1998 and is led by CEO Michel Feraud. Provepharm Life Solutions is an independent pharmaceutical and life‑sciences group created in 1998 and based in Marseille, France. The company provides pharmaceutical‑grade methylene blue in 25 countries and focuses on revitalizing known molecules. Its strategy is to develop its product range, apply its expertise to other molecules, and strengthen its international business. Provepharm ended 2018 with record results and completed its first company acquisition in October 2018, integrating a new product portfolio. Over the next months the company plans to accelerate growth and strengthen its US subsidiary to expand its international presence.

Total raised

$190M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2021